TNF Pharmaceuticals, Inc. (TNFA) Stock
TNFA is no longer traded. TNF Pharmaceuticals was delisted from the Nasdaq in September 2025.
Prices on this page are historical; the last trade was September 24, 2025 at $5.20.
TNF Pharmaceuticals stock price history
TNFA final trading statistics
- Final close
- $5.20
- Final trading day
- Sep 24, 2025
- Market cap at delisting
- $9.60M
- Shares outstanding
- 1.85M
- Final 52-week range
- $0.04 – $8.94
- Avg. volume (final 3 mo.)
- 1,580,426
- All-time high (split-adj.)
- $165312.00 · Jan 2018
- All-time low (split-adj.)
- $0.15 · Jan 2018
- Return since IPO
- -89.1%
- Beta
- 2.28
- Book value / share
- $17.47
- Price / book
- 0.30
TNF Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$23.4M | -$1172.55 |
| FY2023 | $0.00 | -$4.0M | -$564.55 |
| FY2022 | $0.00 | -$15.2M | -$1177.47 |
| FY2021 | $0.00 | -$29.9M | -$3246.57 |
| FY2020 | $0.00 | -$17.6M | -$29936.13 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
TNF Pharmaceuticals stock FAQ
What happened to TNF Pharmaceuticals stock?
TNF Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $5.20 on September 24, 2025.
Is TNFA stock still trading?
No. TNFA was delisted from the Nasdaq in September 2025 and no longer trades on a U.S. exchange.
What was the last price of TNFA stock?
TNFA closed at $5.20 on its final trading day, September 24, 2025, for a market value of about $9.60M.
What were TNF Pharmaceuticals's revenue and earnings in its last full fiscal year?
TNF Pharmaceuticals reported revenue of $0.00 and net income of -$23.4M in fiscal 2024, its last full year as a public company.
When did TNF Pharmaceuticals go public?
TNF Pharmaceuticals, Inc. stock began trading on January 23, 2014.